Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
出版年份 2015 全文链接
标题
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
作者
关键词
-
出版物
Biomed Research International
Volume 2015, Issue -, Pages 1-13
出版商
Hindawi Limited
发表日期
2015-10-24
DOI
10.1155/2015/172458
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway
- (2015) Yanmei Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
- (2015) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
- (2014) A. Garcia-Gomez et al. CLINICAL CANCER RESEARCH
- Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease
- (2014) M. J. Pianko et al. CLINICAL CANCER RESEARCH
- Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
- (2014) Yali Li et al. LEUKEMIA RESEARCH
- Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
- (2014) Ki-Seong Eom et al. Biomed Research International
- The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group
- (2013) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Increasing Bone Sclerosis During Bortezomib Therapy in Multiple Myeloma Patients: Results of a Reduced-Dose Whole-Body MDCT Study
- (2013) Maximilian Schulze et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Targeting the ubiquitin proteasome system in haematological malignancies
- (2013) Lisa J. Crawford et al. BLOOD REVIEWS
- The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling
- (2013) Martin F. Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma
- (2013) R Silbermann et al. LEUKEMIA
- Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
- (2013) Bo Hu et al. PLoS One
- Hypoxia inhibits the differentiation of mesenchymal stem cells into osteoblasts by activation of Notch signaling
- (2012) Ningru Xu et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
- (2012) Enrique M Ocio et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib
- (2012) Maki Uyama et al. GENES TO CELLS
- Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
- (2012) Simone Cenci et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation
- (2012) N Giuliani et al. LEUKEMIA
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
- (2012) Eric Sanchez et al. LEUKEMIA RESEARCH
- Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib
- (2012) Celia R. Berkers et al. MOLECULAR PHARMACEUTICS
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
- (2011) S. D'Souza et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs
- (2011) Claudia P. Miller et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
- (2011) E. C. Lee et al. CLINICAL CANCER RESEARCH
- Treatment Options for Relapsed and Refractory Multiple Myeloma
- (2011) Sagar Lonial et al. CLINICAL CANCER RESEARCH
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- (2011) Noopur Raje et al. CLINICAL CANCER RESEARCH
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
- (2011) Maurizio Zangari et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
- (2011) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Advances in Imaging and the Management of Myeloma Bone Disease
- (2011) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
- (2010) E. Terpos et al. ANNALS OF ONCOLOGY
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma
- (2010) Sung-Eun Lee et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro
- (2010) Thomas Lund et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
- (2010) M. Zangari et al. HAEMATOLOGICA
- The amazing osteocyte
- (2010) Lynda F Bonewald JOURNAL OF BONE AND MINERAL RESEARCH
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
- (2010) E Terpos et al. LEUKEMIA
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo
- (2009) Claire M. Edwards et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling
- (2009) Y.-W. Qiang et al. BLOOD
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
- (2009) T. B. Bartel et al. BLOOD
- Osteo-transcriptomics of human mesenchymal stem cells: Accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis
- (2009) Ester Piek et al. BONE
- The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
- (2009) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- (2008) Angela Pennisi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The direct role of vitamin D on bone homeostasis
- (2008) René St-Arnaud ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- The pathogenesis of the bone disease of multiple myeloma
- (2008) Claire M. Edwards et al. BONE
- Bortezomib in the front-line treatment of multiple myeloma
- (2008) Paul G Richardson et al. Expert Review of Anticancer Therapy
- Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice
- (2008) Siddhartha Mukherjee et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of pathologic fractures on survival in multiple myeloma patients: a case control study
- (2008) Mehmet Sonmez et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions
- (2008) P. Boissy et al. LEUKEMIA RESEARCH
- Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation
- (2008) Matthew J Hilton et al. NATURE MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started